<unk> , sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis. The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).<unk>  was approved for medical use in the European Union in August 2021.
Bimekizumab
Caplacizumab
Ixekizumab
Brolucizumab
Risankizumab
Satralizumab
Tocilizumab
Etaracizumab